Cosentyx and Vaccination Timing
Cosentyx (secukinumab) suppresses parts of the immune system by blocking IL-17A, which can reduce vaccine effectiveness, especially for live vaccines. No specific pause duration is mandated by the manufacturer, Novartis, or FDA labeling, but guidelines recommend timing based on vaccine type to balance infection risk and immune response.[1][2]
Live Vaccines: Hold Cosentyx for 4+ Weeks
Avoid live vaccines (e.g., MMR, varicella, oral polio, yellow fever) during Cosentyx treatment and for several weeks after stopping. Pause Cosentyx at least 4 weeks before vaccination, and do not restart until 4 weeks post-vaccination. This minimizes immunosuppression during the immune response window.[1][3]
Inactivated or mRNA Vaccines: Minimal or No Pause Needed
For non-live vaccines like COVID-19 mRNA shots (Pfizer, Moderna), flu, Tdap, or shingles (Shingrix), no pause is required. Vaccinate while on Cosentyx—response may be blunted, but benefits outweigh risks, per CDC and rheumatology experts. Some boost antibody titers by vaccinating early in the dosing cycle.[2][4]
Restarting Cosentyx After Vaccination
Wait 2-4 weeks post-vaccination before resuming Cosentyx, regardless of vaccine type, to allow peak antibody production. Shorter holds (2 weeks) apply to non-live vaccines in urgent cases; extend to 4 weeks for live ones.[3][5]
What If You're Already on Cosentyx?
Consult your doctor—don't self-pause without guidance, as stopping increases disease flare risk (e.g., psoriasis, psoriatic arthritis). Pre-vaccination testing for immunity or post-vaccination titers can assess response.[2][6]
Special Cases and Patient Concerns
- COVID-19 boosters: No hold needed; vaccinate anytime.[4]
- Pregnancy/pediatrics: Same rules, but prioritize maternal vaccination.
- Surgery or infection: Pause Cosentyx 4 weeks pre-procedure if possible.
Rheumatologists often follow EULAR guidelines: vaccinate before starting biologics if feasible.[5]
[1] Cosentyx Prescribing Information, Novartis, https://www.cosentyx.com
[2] CDC Vaccine Guidelines for Immunocompromised Adults, https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/immunocompromised.html
[3] American College of Rheumatology COVID-19 Vaccine Guidance, https://rheumatology.org
[4] NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov
[5] EULAR Recommendations for Vaccination in Rheumatic Diseases, Annals of Rheumatic Diseases, 2023
[6] DrugPatentWatch.com (Cosentyx patents expire 2032-2034 in key markets), https://www.drugpatentwatch.com/p/tradename/COSENTYX